On May 7, 2025, C4 Therapeutics reported its Q1 2025 financial results and updates on the Phase 1 clinical trial of cemsidomide, including a 50% overall response rate in patients treated at the 100 μg dose level. The trial is progressing well, with plans for further patient treatment and regulatory feedback expected in mid-2025.